Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Steering improved outcomes in non-driver mutation lung cancer: Progress and challenges

IASLC 19th World Conference on Lung Cancer - Industry satellite symposium

Chaired by Mark A. Socinski

Held on Sunday 23rd September at the Metro Convention Centre, Toronto, CA

The IASLC World Conference on Lung Cancer is a world-renowned platform for the presentation and discussion of new science in the field of lung cancer and thoracic oncology. The presentations from this associated symposium discussed the latest in non-driver mutation lung cancer, from histologic and molecular profiling, through to current and emerging treatment options, including those for patients with refractory and aggressive disease. The objective was to discuss the challenges that this patient group presents, and the progress being made to overcome them.

Complete the quiz at the end of this summary to earn 0.75 AMA PRA Category 1 CreditsTM.

© Springer Healthcare IME

12-10-2018 | Video | Gallery

Faculty interviews

Scroll below to see interviews with Mark Socinski, Keith Kerr, James Yang and Corey Langer

Professor Mark Socinski, Florida Hospital Cancer Institute, Orlando, FL, USA (symposium chair)

 

Professor Keith Kerr, Aberdeen University Medical School, Scotland, UK

 

Professor Mark Socinski, Florida Hospital Cancer Institute, Orlando, FL, USA (symposium chair)

 

Professor James Yang, National Taiwan University, Taipei City, Taiwan

 

Professor Corey Langer, University of Pennsylvania, Philadelphia, PA, USA

 
Mark Socinsky
Keith Kerr
Mark Socinsky
James Yang
Corey Langer

Faculty bios

Learning objectives

The aims of the symposium were to help delegates to be able to:

  • Describe how the histologic and molecular profiling may help to individualize care in nonsquamous and squamous NSCLC from the first-line setting through subsequent lines of treatment
  • Appraise data from the on-going trials in the field of non-driver lung cancer and understand how they can maximize patient outcomes
  • Debate the optimal sequencing and the pros and cons of the different available therapies for lung cancer patients without an actionable oncogenic driver
  • Identify patients with refractory and/or aggressive disease and explain how to optimally sequence treatment for these patients in daily clinical practice

Educational grant

This program was made possible thanks to an independent educational grant from Eli Lilly and Company.

Produced by Springer Healthcare IME.

Contact us

Email: IME@springer.com
Telephone +44 (0) 203 192 2023
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK

Image Credits